ThisCART

ThisCART is a clinical-stage biotechnology company focused on developing next-generation, off-the-shelf (allogeneic) CAR-T cell therapies for the treatment of hematologic malignancies and solid tumors. The company utilizes its proprietary ThisCART platform to engineer T cells that can be administered to patients without the need for complex, patient-specific manufacturing, potentially reducing costs and increasing accessibility. Their lead candidate, ThisCART19, is currently being evaluated in clinical trials for B-cell non-Hodgkin lymphoma and other B-cell related cancers. By addressing the limitations of autologous CAR-T therapies, such as long manufacturing lead times and high production costs, ThisCART aims to provide a more scalable and efficient solution for cancer immunotherapy.